Kodiak Sciences (NASDAQ:KOD) Upgraded to Sell at Wall Street Zen

Wall Street Zen upgraded shares of Kodiak Sciences (NASDAQ:KOD) from a strong sell rating to a sell rating in a research report released on Sunday,Wall Street Zen reports.

KOD has been the topic of a number of other research reports. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $103.00 price objective on shares of Kodiak Sciences in a report on Wednesday, September 30th. JPMorgan Chase & Co. increased their target price on Kodiak Sciences from $56.00 to $66.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. HC Wainwright lifted their price target on Kodiak Sciences from $58.00 to $96.00 and gave the company a “buy” rating in a research note on Monday, September 28th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $112.00 price target on shares of Kodiak Sciences in a research note on Monday, September 28th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $100.43.

Kodiak Sciences Stock Performance

Shares of Kodiak Sciences stock opened at $94.45 on Friday. Kodiak Sciences has a one year low of $10.94 and a one year high of $104.00. The company has a market cap of $5.94 billion, a P/E ratio of -22.54 and a beta of 2.03. The firm has a fifty day moving average of $43.53 and a two-hundred day moving average of $39.80.

Kodiak Sciences (NASDAQ:KOD) last issued its earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.09). As a group, equities analysts predict that Kodiak Sciences will post -3.97 earnings per share for the current year.

Insider Activity

In other news, Director Bros. Advisors Lp Baker bought 807,840 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The shares were purchased at an average price of $72.57 per share, for a total transaction of $58,624,948.80. Following the completion of the transaction, the director owned 19,121,134 shares in the company, valued at $1,387,620,694.38. The trade was a 4.41% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased a total of 1,941,755 shares of company stock worth $156,986,026 over the last quarter. Corporate insiders own 44.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Baker BROS. Advisors LP boosted its holdings in shares of Kodiak Sciences by 15.1% during the fourth quarter. Baker BROS. Advisors LP now owns 19,919,186 shares of the company’s stock worth $556,940,000 after purchasing an additional 2,608,696 shares during the last quarter. BlackRock Inc. acquired a new position in Kodiak Sciences in the second quarter valued at $161,113,000. Jupiter Topco LLC acquired a new position in Kodiak Sciences in the second quarter valued at $59,507,000. Janus Henderson Group PLC lifted its position in Kodiak Sciences by 32.5% during the first quarter. Janus Henderson Group PLC now owns 1,325,457 shares of the company’s stock worth $50,540,000 after buying an additional 325,457 shares during the period. Finally, ICONIQ Capital LLC purchased a new position in Kodiak Sciences during the second quarter worth about $49,345,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Kodiak Sciences News Roundup

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Positive Phase 3 results remain the primary catalyst. Kodiak’s Zenkuda/KSI-501 reportedly met key goals in the DAYBREAK trial for wet age-related macular degeneration, outperforming or matching Eylea on important endpoints. The results support plans to pursue a biologics license application and strengthen the company’s potential position in the large retinal-disease market. Kodiak Sciences more than doubles on eye disease trial results
• Positive Sentiment: Analyst price targets have moved higher. Kodiak’s consensus target reportedly increased 65.16% to $117.50. Jefferies maintains a Buy rating with a $112 target, while HC Wainwright raised its target to $96 and lifted longer-term earnings estimates based on the trial opportunity. Kodiak Sciences consensus price target increased
• Positive Sentiment: Insider buying provides an additional confidence signal. Director Bros. Advisors LP Baker purchased 33,726 shares at about $85.05, following several larger purchases totaling roughly 1.94 million shares in late September. Kodiak Sciences insider purchase
• Neutral Sentiment: Expectations for future earnings are being reset. Brokers are forecasting continued losses in the near term, but the potential commercial impact of Zenkuda has led to substantially improved FY2027-and-beyond estimates. Kodiak Sciences FY2027 earnings expectations
• Negative Sentiment: The stock’s rapid advance raises near-term correction risk. Shares have climbed from roughly $37 to above $100 in about a month and have delivered a gain of more than 500% over the past year. Such momentum can encourage profit-taking, while Kodiak remains an unprofitable biotechnology company with execution, regulatory and financing risks. Kodiak Sciences comeback and dealmaking

About Kodiak Sciences

Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company’s research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye.

Kodiak’s lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.